DermatologyInvestigational

SNAP-8 (Acetyl Octapeptide-3)

Overview

SNAP-8 is an elongated derivative of Argireline, consisting of eight amino acids (Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2) designed to further inhibit SNARE complex formation and catecholamine-mediated neurotransmitter release. By extending the peptide sequence, the molecule is hypothesized to achieve enhanced binding and greater reduction in muscle contraction intensity in facial expression zones. Like its hexapeptide predecessor, it is positioned as a non-invasive topical anti-wrinkle agent.

Key Research Findings

In vitro assays have demonstrated that acetyl octapeptide-3 can reduce neurotransmitter release in cell-free models at higher potency than acetyl hexapeptide-8. Manufacturer-sponsored clinical studies have reported wrinkle depth reductions of approximately 60 percent in some participants after 28 days, though independent peer-reviewed replication is absent. Standardized efficacy benchmarks and head-to-head comparisons with established treatments have not been published.

Route of Administration

Topical

Regulatory Status

Investigational

Interested in SNAP-8 (Acetyl Octapeptide-3)?

Find a verified provider experienced with SNAP-8 (Acetyl Octapeptide-3) protocols in your area. All providers are credentialed and use compliant sourcing.

Find a SNAP-8 (Acetyl Octapeptide-3) Provider

Related Peptides

Afamelanotide (Scenesse)

FDA Approved

A synthetic 13-amino acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH) with a substitution of norleucine at position 4 that confers enhanced potency and enzymatic stability. Afamelanotide activates melanocortin-1 receptors (MC1R) on melanocytes, stimulating eumelanin production independent of UV exposure. The resulting increase in skin eumelanin provides photoprotection by absorbing UV radiation and scavenging reactive oxygen species.

Argireline (Acetyl Hexapeptide-8)

Investigational

Argireline is a synthetic six amino acid peptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) designed to attenuate neurotransmitter release at the neuromuscular junction. It functions as a competitive inhibitor of the SNARE complex, reducing catecholamine release and potentially diminishing muscle contraction intensity in facial expression muscles. This mechanism provides a topical alternative rationale to botulinum toxin for addressing expression lines, though with markedly lower potency.

Matrixyl (Palmitoyl Pentapeptide-4)

Investigational

Matrixyl is a lipopeptide composed of a pentapeptide sequence (Lys-Thr-Thr-Lys-Ser) attached to a palmitic acid moiety to enhance dermal penetration. It is proposed to stimulate fibroblast activity and upregulate synthesis of extracellular matrix components including collagen types I and III, fibronectin, and hyaluronic acid. The peptide serves as a matrikine fragment mimetic, signaling tissue remodeling pathways in aged or photodamaged skin.

Matrixyl 3000

Investigational

Matrixyl 3000 is a proprietary combination of two lipopeptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). The formulation is designed to synergistically promote collagen and fibronectin synthesis while reducing interleukin-6 mediated inflammation in dermal fibroblasts. Both peptides carry palmitic acid for enhanced lipid solubility and stratum corneum permeation.